Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aptiv Solutions Growing: Opens New Office in North Carolina

Published: Monday, December 10, 2012
Last Updated: Monday, December 10, 2012
Bookmark and Share
New office is located at 4505 Emperor Boulevard in the Imperial Center.

Aptiv Solutions has announced the opening of a new office in Durham, North Carolina.

The new office is located at 4505 Emperor Boulevard in the Imperial Center, an elite business park convenient to Raleigh, Durham, Chapel Hill, Cary and Research Triangle Park.

Aptiv Solutions and its subsidiary Trio Clinical Resourcing previously resided in separate offices in Raleigh and Morrisville.

The decision to combine the offices arose from growth of staff and the desire to co-locate the North Carolina based teams.

The new office includes team members from the clinical, data management and biostatistics, regulatory, translational sciences, medical consulting, pharmacovigilance, quality assurance, proposal development, information technology, finance, business development and human resources teams for Aptiv Solutions and the Trio Clinical Resourcing team.

“We are delighted to have our Aptiv Solutions and Trio Clinical Resourcing teams all under one roof in the new Durham, North Carolina office,” commented Pat Donnelly, Chairman and CEO of Aptiv Solutions.

Donnelly continued, “We continue to experience rapid growth as we expand to meet the expansion in our client base. Our new office not only accommodates our current staff levels, but allows for the anticipated future growth of our North Carolina operations”.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aptiv Solutions to be Acquired by ICON
Combined companies provide unrivalled capabilities for adaptive and medical device trials worldwide.
Monday, March 31, 2014
Tufts CSDD Study Finds Adoption of Adaptive Clinical Trial Designs is Increasing
Report shows growing acceptance by pharmaceutical companies and regulatory agencies.
Friday, May 24, 2013
Scientific News
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
First Made-in-Singapore Cancer Drug Enters Clinical Testing
The drug prevents cancer progression and paves the way for new advancements in cancer therapeutics.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!